Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of tgAAC09, an HIV Vaccine Containing Clade C Gag-PR-ΔRT DNA in an Adeno-Associated Virus (AAV) Capsid, Administered Twice, at Three Dosage Levels and Two Dosing Intervals.

Next Previous
Trial Profile

A Phase II, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of tgAAC09, an HIV Vaccine Containing Clade C Gag-PR-ΔRT DNA in an Adeno-Associated Virus (AAV) Capsid, Administered Twice, at Three Dosage Levels and Two Dosing Intervals.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TgAAC 09 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics

Most Recent Events

  • 16 May 2009 Targeted Genetics Corporation added as trial sponsor, additional lead trial investigator identified as reported by ClinicalTrials.gov.
  • 28 Apr 2009 Actual end date (1 Dec 2007) added as reported by Clinicaltrials.gov record.
  • 28 Apr 2009 Actual initiation date (1 Oct 2005) added as reported by Clinicaltrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top